C4 Imaging LLC has chosen leading specialty chemicals company Evonik Corporation and its Resource Efficiency segment’s VESTAKEEP® PEEK polymer technology in the design of Sirius™, a recently developed Positive-Signal Magnetic Resonance Imaging (MRI) Marker used during the treatment of prostate cancer.
C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research (“SBIR”) grant from the National Cancer Institute of the National Institutes of Health (“NIH”). Entitled “Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer”, the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging’s commercially available Sirius™ MRI Marker.
“This first implant is a significant milestone,” said Andrew Bright, President and CEO of C4 Imaging. “MR imaging of the implanted Sirius™ MRI Markers was successful and the clinical team were able to localize the implanted seeds.” He added, “We were delighted to partner with IsoRay™ Medical for this first implant.
C4 Imaging will partner with Florida-based AnazaoHealth Corporation, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius™ MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.
C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel positive-signal, MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure.